An Open-label, Single Arm Study to Evaluate the Week 48 Efficacy and Safety of a Two-drug Regimen of Dolutegravir/Lamivudine (DTG/3TC) as a Fixed Dose Combination (FDC), in Antiretroviral Therapy (ART)-Naive HIV-1-infected Adolescents, ≥12 to <18 Years of Age Who Weigh at Least 40 kg
Phase of Trial: Phase III
Latest Information Update: 01 Nov 2019
Price : $35 *
At a glance
- Drugs Dolutegravir/lamivudine (Primary)
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Sponsors ViiV Healthcare
- 19 Jun 2019 Planned End Date changed from 29 Dec 2023 to 30 Jun 2023.
- 19 Jun 2019 Planned primary completion date changed from 31 Jul 2020 to 1 Oct 2020.
- 19 Jun 2019 Status changed from not yet recruiting to recruiting.